BEXIMCO PHARMA.GDR REGS 1 Defensive Interval Ratio
BEXIMCO PHARMA.GDR REGS 1 defensive interval ratio. BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Defensive Interval Ratio of 150 days as of December 2024. Defensive assets of €4.75 Billion (cash €-, short-term investments €700.00 Million, receivables €4.05 Billion) cover 150 days of daily cash needs of €31.61 Million/day. See BEXIMCO PHARMA.GDR REGS 1 short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Defensive Interval Ratio of BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
Defensive interval ratio of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024. This chart shows how BEXIMCO PHARMA.GDR REGS 1's Defensive Interval Ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 150 days, meaning defensive assets of €4.75 Billion can fund 150 days of operations without new revenue. Check R2WA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
BEXIMCO PHARMA.GDR REGS 1 Defensive Interval Ratio by Year (2021–2024)
BEXIMCO PHARMA.GDR REGS 1 defensive interval ratio by year from 2021 to 2024. The table below presents the year-by-year Defensive Interval Ratio for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For the complete balance sheet picture, see how large is BEXIMCO PHARMA.GDR REGS 1's balance sheet.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2024 | 140 days | €3.66 Billion | €26.20 Million/day | €- | €200.00 Million | ▲ +47 days |
| 2023 | 93 days | €3.37 Billion | €36.34 Million/day | €- | €- | ▲ +8 days |
| 2022 | 85 days | €2.96 Billion | €34.89 Million/day | €- | €- | ▼ -21 days |
| 2021 | 106 days | €2.73 Billion | €25.62 Million/day | €- | €- | — |